Aileron Ther­a­peu­tics files for a $69M IPO as new of­fer­ings heat up

Aileron Ther­a­peu­tics has set out to raise $69 mil­lion in the lat­est biotech IPO to hit the street.

Their lead drug — AL­RN-6924 — is fo­cused on p53, a fa­mil­iar and very frus­trat­ing tar­get in the can­cer R&D world. Still in ear­ly stud­ies, Aileron has gath­ered a col­lec­tion of ini­tial pa­tient re­spons­es to the drug, which tar­gets MD­MX and MDM2.

Aileron has had a low pro­file for the last few years. It’s jump­ing in­to the IPO queue now af­ter a grow­ing line­up of drug de­vel­op­ers have sought in­vestors’ em­brace, with vary­ing but gen­er­al­ly pos­i­tive re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.